24 Feb, 2026EXPERT COMMENTARYFrom innovation to value realization: The biotech market in a new phaseFind out more
After several years characterized by elevated capital costs, valuation pressure and pronounced risk...
Publisher
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
After several years characterized by elevated capital costs, valuation pressure and pronounced risk...
Source route
Continue on bbbiotech.ch
Leave the platform to read the original full article on the publisher site.
Source: BB Biotech
Scope: Industry
Related coverage
More related coverage
Generic Drug Labeling Carve-Out Scorecard
By Kurt R. Karst – With the recent litigation surrounding FDA’s approval of ANDAs for generic versio...